Peptides DB
Research-centric peptide and protocol reference hub

ARA 290 vs Gonadorelin (GnRH)

Updated July 27, 2026 · Reviewed by the PeptidesDB Editorial team

ARA 290: Research use — not FDA-approvedGonadorelin (GnRH): Research use — not FDA-approved

A data-driven comparison of ARA 290 and Gonadorelin (GnRH) (also searched as Gonadorelin (GnRH) vs ARA 290) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

ARA 290 centers on healing, while Gonadorelin (GnRH) leans toward healing. On indexed research, Gonadorelin (GnRH) is ahead (ARA 290: 13 studies, Human evidence; Gonadorelin (GnRH): 18, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • ARA 290 is strongest for healing; Gonadorelin (GnRH) for healing.
  • Evidence: ARA 290 Human evidence (13 studies) vs Gonadorelin (GnRH) Human evidence (18).
  • Both are research-use compounds — not FDA-approved.

Effect profiles, overlaid

ARA 290: Healing 4.0, Muscle 0.0, Metabolic 0.0, Neuro 4.0, Sleep 0.0, Immune 3.0, Skin 0.0 — Gonadorelin (GnRH): Healing 2.0, Muscle 0.0, Metabolic 0.0, Neuro 1.0, Sleep 0.0, Immune 0.0, Skin 0.0Healing & recovery — 4.0 / 5 · ARA 290Neuro & mood — 4.0 / 5 · ARA 290Inflammation & immune — 3.0 / 5 · ARA 290Healing & recovery — 2.0 / 5 · Gonadorelin (GnRH)Neuro & mood — 1.0 / 5 · Gonadorelin (GnRH)HealingMuscleMetabolicNeuroSleepImmuneSkin
ARA 290Gonadorelin (GnRH)

At a glance

ARA 290Human evidence

Tissue-Protective Peptide | Innate Repair Receptor Agonist

Strongest: HealingStudies: 13Level: Extensively Studied
Gonadorelin (GnRH)Human evidence

Gonadotropin-Releasing Hormone | GnRH Agonist

Strongest: HealingStudies: 18Level: Extensively Studied

ARA 290 vs Gonadorelin (GnRH): side-by-side

MetricARA 290Gonadorelin (GnRH)
ClassHealingSexual Health
Regulatory statusResearch use onlyResearch use only
Evidence gradeHuman evidenceHuman evidence
Studies indexed1318
Research levelExtensively StudiedExtensively Studied
Strongest effectHealing & recoveryHealing & recovery
Healing & recovery4.02.0
Muscle & body comp0.00.0
Metabolic & appetite0.00.0
Neuro & mood4.01.0
Sleep & circadian0.00.0
Inflammation & immune3.00.0
Skin & aesthetics0.00.0

▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).

Mechanism & pharmacokinetics

PropertyARA 290Gonadorelin (GnRH)
Mechanismβ-common receptor interactionGnRH receptor agonist
RouteSubcutaneous injection
Half-life~20 min

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is Gonadorelin (GnRH)?

Gonadorelin is synthetic GnRH, a decapeptide that stimulates pituitary release of LH and FSH in pulsatile fashion — used diagnostically and to support the reproductive hormone axis.

Full Gonadorelin (GnRH) profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingARA 2904.0/5 effect signal
NeuroARA 2904.0/5 effect signal
InflammationARA 2903.0/5 effect signal

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack ARA 290 and Gonadorelin (GnRH)?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

ARA 290 vs Gonadorelin (GnRH): side effects

ARA 290

No community-reported effects logged yet.

Gonadorelin (GnRH)

No community-reported effects logged yet.

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

ARA 290 has 13 approved studies indexed (Human evidence), and Gonadorelin (GnRH) has 18 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is ARA 290 or Gonadorelin (GnRH) better?

It depends on your goal. ARA 290 is strongest for healing; Gonadorelin (GnRH) for healing. Gonadorelin (GnRH) has more indexed studies (18). See the goal-by-goal breakdown above.

Which has more research, ARA 290 or Gonadorelin (GnRH)?

ARA 290 has 13 approved studies indexed (Human evidence); Gonadorelin (GnRH) has 18 (Human evidence). Higher counts mean more to read, not proven superiority.

Can you stack ARA 290 and Gonadorelin (GnRH)?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of ARA 290 vs Gonadorelin (GnRH)?

ARA 290: no community-reported effects logged yet. Gonadorelin (GnRH): none logged yet. These are anonymous reports, not incidence rates — see each profile.

Is ARA 290 or Gonadorelin (GnRH) FDA-approved?

ARA 290 is a research-use compound and is not FDA-approved. Gonadorelin (GnRH) is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is Gonadorelin (GnRH) better than ARA 290?

For healing, Gonadorelin (GnRH) has the edge; for healing, ARA 290 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

ARA 290 and Gonadorelin (GnRH) are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 27, 2026.